Phase 1 Study to be Conducted in Advanced Cancer Patients
ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1, open-label, continuous dosing study with its oral cell cycle inhibitor, MKC-1, in patients with advanced or metastatic solid tumors. The clinical trial will be conducted at the University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center. Dr. Glenn Liu, Assistant Professor of Medicine, University of Wisconsin, will serve as principal investigator.
The purpose of the dose-escalation trial is to determine the maximum tolerated dose (MTD) of MKC-1 administered orally twice a day continuously in advanced or refractory solid tumor patients. Response and/or tumor marker improvement will also be evaluated. Up to 24 patients with metastatic or unresectable solid tumors for which standard curative measures do not exist or are no longer effective will be enrolled.
MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. To date, MKC-1 has been evaluated in over 400 patients in multiple Phase 1 and 2 clinical trials.
MKC-1 has been
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved